Yeah. Thank you, Jennifer. Maybe before I jump in, I'll follow your lead and just offer my appreciation and thanks to our colleagues in innovative med and R&D. We had a heck of a year for the pipeline, 27 approvals, 49 submissions, 15 out of 17 positive phase 3s, more than 90% ...
will then provide an overview of our pipeline advancements, cash position, capital allocation priorities, and guidance for 2024, as well as qualitative considerations for 2025. Jennifer Taubert, John Reed, and Tim Schmid, our innovative
And looking into 2024, the remainder of the year, and also into 2025, we have some very exciting news in our pipeline. Some of them have been already commented. For example, the first chemo-free regimen as first-line in EGFR mutated non-small lung cancer. We will be presenting the data...
Innovative Medicine pipeline Learn more Innovative Medicine pipeline Environmental, social, and governance Learn more about Environmental, social, and governance Information on tax basis following Kenvue separationQuestions? Please contact us: 1-800-950-5089 investor-relations@its.jnj.com ...
对真性红细胞增多症中rusfertide的全球3期VERIFY研究正在进行中。根据与武田于2024年1月签订的全球合作和许可协议,Rusfertide将与武田共同开发和共同商业化。该协议将在《哈特-斯科特-罗迪诺法案》规定的任何适用等待期终止或到期时生效。 More information on Protagonist, its pipeline drug candidates and clinical ...
Our pipeline We aim to deliver truly remarkable medicines that provide value to patients, healthcare professionals and healthcare systems. Read more Data science & digital health We’re transforming how we discover, develop and deliver new therapies — helping bring transformative medicines to ...
Our pipeline We aim to deliver truly remarkable medicines that provide value to patients, healthcare professionals and healthcare systems. Read more Data science & digital health We’re transforming how we discover, develop and deliver new therapies — helping bring transformative medicines to ...
Additionally, the spinoff also generated over $13 billion for JNJ which can provide resources for internal pipeline enhancement or growth through collaborations and acquisitions. Even though the spinoff led to a decline in JNJ's sales and earnings forecasts for the year, the company's shares have...
Total Debt (Recent Filing)$35.75B Price to Earnings (P/E)24.7 Beta0.25 Next Earnings Jan 22, 2025 EPS Estimate $2.02 Last Dividend Ex-Date Nov 26, 2024 Dividend Yield3.28% Johnson & Johnson News The Fly J&J trial news may have positive read for Neumora Therapeutics, says RBC Capital ...
JNJJohnson & Johnson Latest Stock Analysis Analyze With AI Follow419.54K followers $162.302.62 (+1.64%)4:00 PM 02/21/25 NYSE |$USD |Post-Market:$162.21-0.09 (-0.06%)7:59 PM SummaryRatingsFinancialsEarningsDividendsValuationGrowthProfitabilityMomentumPeersOptionsCharting ...